Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: Recommendations of the College of American Pathologists

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 11, 2002, Pages 1415-1423

  Warkentin, Theodore E ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b Hamilton Health Sciences   (Canada)

^c Service of Clinical Hematology   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

CONFERENCE PAPER; DISEASE ASSOCIATION; HUMAN; IMMUNOASSAY; LABORATORY TEST; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS;

BLOOD PLATELETS; HEPARIN; HUMANS; MONITORING, PHYSIOLOGIC; PLATELET COUNT; PRACTICE GUIDELINES; SENSITIVITY AND SPECIFICITY; THROMBOCYTOPENIA; THROMBOPHILIA;

EID: 0036881566     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127:804-812.
2. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330-1335.
4. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost. 1998;79:1-7.
5. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:43-86.
6. Warkentin TE. Heparin-induced skin lesions. Br J Haematol. 1996;92:494-497.
7. Warkentin TE. Heparin-induced thrombocytopenia, skin lesions, and arterial thrombosis: a new clinical syndrome [abstract]. Can J Cardiol. 1996;12(suppl E):151E.
8. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:231-269.
9. Warkentin TE, Sheppard JI, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000;96:1703-1708.
10. Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R. Determination of heparin-platelet 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia. Br J Haematol. 2001;113:886-890.
11. Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:167-187.
12. Amiral J, Meyer D. Heparin-dependent antigens in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:137-148.
13. Horne MK III. Nonimmune heparin-platelet interactions: implications for the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:123-136.
14. Suh JS, Malik MI, Aster RH, Visentin GP. Characterization of the humoral immune response in heparin-induced thrombocytopenia. Am J Hematol. 1997;54:196-201.
15. Amiral J, Pouplard C, Vissac AM, Walenga JM, Jeske W, Gruel Y. Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation. Br J Haematol. 2000;109:336-341.
16. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96:182-187.
17. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83:1535-1541.
18. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691-3699.
19. Warkentin TE, Sheppard JI. Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgC platelet agonists: a comparison with standard platelet agonists. Platelets. 1999;10:319-326.
20. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest. 1994;93:81-88.
21. Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost. 1994;71:247-251.
22. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood. 2001;97:3300-3302.
23. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 2001;98:1252-1254.
24. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:291-322.
25. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344:1286-1292.
26. Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med. 2001;135:502-506.
27. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
28. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparininduced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol. 1997;56:12-16.
29. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106:629-635.
30. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy. Eur J Clin Pharmacol. 1997;52:183-189.
31. Warkentin TE, Levine MN, Hirsh J, Klama LN, Kelton JG. Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: analysis of a clinical trial [abstract]. Blood. 1995;86(suppl 1):537a.
32. Warkentin TE, Hong AP. Frequency of upper limb deep venous thrombosis (UL-DVT) in relation to central venous catheter (CVC) use in patients with heparin-induced thrombocytopenia (HIT): evidence for interaction of systemic (HIT) and local (CVC) prothrombotic risk factors [abstract]. Blood. 1998;92(suppl 1):500a-501a.
33. Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol. 1999;62:44-48.
34. Lee DP, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:87-121.
35. Pouplard C, May MA, Iochmann S, et al. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparininduced thrombocytopenia. Circulation. 1999;99:2530-2536.
36. Lee DP, Warkentin TE, Denomme GA, Hayward CPM, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. BrJ Haematol. 1996;85:724-731.
37. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69:344-350.
38. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2000;10:S35-S45.
39. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
40. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:371-379.
41. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66:734-736.
42. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion. 1994;34:381-385.
43. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost. 1999;81:625-629.
44. Polgár J, Eichler P, Greinacher A, Clemetson KJ. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by sera from heparin-induced thrombocytopenia patients. Blood. 1998;91:549-554.
45. Warkentin TE. History of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:1-18.
46. Favaloro EJ, Bernal-Hoyos E, Exner T, Koutts J. Heparin-induced thrombocytopenia: laboratory investigation and confirmation of diagnosis. Pathology. 1992;24:177-183.
47. Goodfellow KJ, Brown P, Malia RG, Hampton KK. A comparison of laboratory tests for the diagnosis of heparin-induced thrombocytopenia [abstract]. Br J Haematol. 1998;101(suppl 1):89.
48. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost. 1992;68:95-96.
49. Collins JL, Aster RH, Moghaddam M, Piotrowski MA, Strauss TR, McFarland JG. Diagnostic testing for heparin-induced thrombocytopenia (HIT): an enhanced platelet factor 4 complex enzyme linked immunosorbent assay (PF4 ELISA) [abstract]. Blood. 1997;90(suppl 1):461a.
50. Amiral J, Worf M, Fischer AM, Boyer-Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol. 1996;92:954-959.
51. Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost. 1998;80:292-297.
52. Vun CM, Evans S, Chesterman CN. Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin. Br J Haematol 2001;112:69-75.
53. Meyer O, Salama A, Pittet N, Schwind P. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet. 1999;354:1525-1526.
54. Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A. The ID microtyping system for detection of heparin-induced antibodies in comparison with functional and antigenic assays [abstract]. Ann Hematol. 2001;80(suppl):A15.
55. Amiral J, Pernaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low molecular weight heparin. Am J Hematol. 1996;52:90-95.
56. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242-1246.
57. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of auto-antibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood. 1996;88:410-416.
58. Warkentin TE. Pseudo-heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:271-289.
59. Warkentin TE. Venous limb gangrene during warfarin treatment of cancerassociated deep venous thrombosis. Ann Intern Med. 2001;135:589-593.
60. Harenberg J, Wang L, Hoffmann U, Huhle G, Feuring M. Improved laboratory confirmation of heparin-induced thrombocytopenia type II: time course of antibodies and combination of antigen and biologic assays. Am J Clin Pathol. 2001;115:432-438.
61. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecularweight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119(suppl):64S-94S.
62. Warkentin TE. Heparin-induced thrombocytopenia: yet another treatment paradox? Thromb Haemost. 2001;85:947-949.
63. Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2nd ed. New York, NY: Marcel Dekker Inc; 2001:349-380.